Oncology

MT-101 is designed for quick delivery to patients with a vein-to-vein time of 8 days.

The medical oncologists at Washington University School of Medicine in St. Louis discussed surprising findings from their retrospective study.

Schlechter discussed the potential advantages of TAC01-HER2 over current standards of care.

TIDAL-01 will be evaluated in patients with advanced or metastatic breast carcinoma, colorectal adenocarcinoma, or uveal melanoma.

Cellular Biomedicine group developed the therapy after efficacy was seen with Iovance’s lifilecuel in solid tumor studies.

Schlechter discussed the design of the TACTIC-2 clinical trial for patients with HER2-positive solid tumors.

Shah explained that the trial is unique due to its inclusion of patients with MRD–positive B-ALL.

The chief executive officer of Chimera Bioengineering discussed CBIO-007 and its planned IND submission for colorectal and triple negative breast cancer.

RZ-001 previously received IND clearance from the South Korean Ministry of Food and Drug Safety in June.

The decision comes after strategic uncertainty regarding a review of preliminary clinical data from GSK’s lete-cel product candidate trial.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Cells produced by this method were also shown to be more potent in animal models than cells made with typical processes.

As we learn more about genomics and identify more genes tied to rare disorders, the role of genetic counselors will become even more critical.

The senior vice president of Research & Early Development at Notch Therapeutics discussed the company’s approach to overcoming the drawbacks of autologous cell therapies.

The decision comes after a previous clinical hold delayed key medical milestones in the KEYNOTE-B79 trial.

The medical oncologists at Washington University School of Medicine in St. Louis discussed background to their research on associations between neurofilament light and neurotoxicity.

Review top news and interview highlights from the week ending October 21, 2022.

In preclinical research, T-cells bearing TK-8001's TCR showed better in vivo antitumor activity than T-cells incorporating human donor-derived TCRs.

The first 6 patients dosed in the ANTLER trial had a 50% CR rate at 6 months.

ITIL-306 utilizes a CoStAR molecule intended to improve cytokine release, cytolytic activity, and proliferation of TILs.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The executive director of Hemophilia Foundation Southern California discussed issues with minorities accessing care for rare diseases and strategies to mitigate them.

NKGen plans to initiate a phase 1 trial pd SNK02 in the first quarter of 2023.

The approval was based on data from ZUMA-7, a phase 3 clinical trial.

With so many therapies on the horizon, the clinical and patient communities need to be adequately prepared to support them.